Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
✅ Otsuka’s confirmatory kidney disease data: The drugmaker said Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study in patients with IgA nephropathy (IgAN). The treatment increased the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.